IGHE and asthma: Several biomarkers of type 2 inflammation, such as FeNO, serum IgE, blood or sputum eosinophils, and serum periostin distinguish type 2-high and type 2-low asthma phenotypes and also predict the responsiveness to type 2 cytokine-targeted therapy [27].